nach oben

Medical Oncology

Erschienen in:

01.12.2007 | Original Paper

The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS

verfasst von: Gordana Bogdanović, Dimitar Jakimov, Bratislav Stojiljkovic, Vladimir Jurišić

Erschienen in: Medical Oncology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

We report on cell growth, morphology, and immunocytochemistry of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome who had no overt leukemia post-MDS phase. This cell population consisted of fast-growing mononuclear cells. Standard cytochemistry methods for detection of MPO, lipids, glycogen and ANAE gave results as follows: MPO and SBB negative while PAS and ANAE positive. Positive cytochemical staining and immunophenotype analyses indicated that PC-MDS cells have some characteristics of the early myeloid precursor cell. As the first t-MDS derived cell line it could be a new tool in evaluation of complex biology of MDS and also serves as a model for diverse in-vitro research.

Drexler HG. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leukemia Res 1999;24:109–15CrossRef

Stefan F, Hagop MK. Chronic Leukemias: section 3: myelodisplastic syndromes. In: DeVita T Jr, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology, 7th ed. (electronic version CD). Philadelphia: Lippincott Williams & Wilkins; 2005. Chapter 43: Section 3

Lasky J, Sakamoto KM. Topics in pediatric leukemia-myelodisplastic and myeloproliferative disorders of childhood. Medscape General Med 2005;7(1):1–6

Delforge M. Understanding the pathogenesis of myelodysplastic syndromes. Hematol J 2003;4:303–9PubMedCrossRef

Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15 ^INK4b, HIC1, CDH1, and ER is frequent in myelodyspalstic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23–32PubMedCrossRef

Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–99

Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001

Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005;10(issue suppl. 1):258–69

Nagai M, Fujita M, Ikeda T, et al. Alterations of p53 and Rb genes in a novel human GM-CSF-dependent myeloid cell line (OHN-GM) established from therapy-related leukemia. Br J Haematol 1997;98:392–8

10.

Klobusicka M, Kusenda J, Babusikova O. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis. Neoplasma 2005;52:211–8PubMed

11.

Bogdanovic G, Jurisic V, Kraguljac N, Mrdjanovic N, Jakimov D, Krtolica K, Dragic M, Magic Z, Stoiljkovic B, Andrejevic Lj, Srdic T, Baltic M, Popovic S. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patients with therapy related myelodisplastic syndrome. Leukemia Res (in press) 2007;doi: 10.1016/j.leukres.2007.01.012

12.

Jurisic V, Bogdanovic G, Srdic T, Jakimov D, Mrdanovic J, Baltic M, Baltic VB. Modulation of TNF-α activity in tumor PC cells using anti-CD45 and anti-CD95 monoclonal antibodies. Cancer Lett 2004;14:55–61CrossRef

13.

Drexler HG, Matsuo Y. Giudelines for the characterization and publication of human malignant hematopoietic cell lines. Leukemia 1999;13:835–42PubMedCrossRef

14.

Béné M-C, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001;113:737–45

15.

Klobusicka M. Reliability and limitations of cytochemistry in diagnosis of acute myeloid leukemia. Neoplasma 2000;47:329–34PubMed

16.

Lepelley P, Preudhomme C, Sartiaux C, et al. Immunological detection of myeloperoxidase in poorly differentiated acute leukemias. Eur J Haematol 1993;50:155–9

17.

Van Der Schoot CE, Daams GM, Pinkster J, Vet R, Von Dem Borne AEG. Monoclonal antibodies against myeloperoxidase are valuable immunological reagents for the diagnosis of acute myeloid leukemia. Br J Haematol 1990;74:173–8

18.

Matsuo T, Kuriyama K, Miyazaki Y, et al. Japan Adult Leukemia Study Group. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia 2003;17:1538–43PubMedCrossRef

19.

Jurisic V, Bogunovic M, Colovic N, Colovic M. Indolent course of the cutaneous Hodgkins’s disease. J Cutan Pathol 2005;32:176–8PubMedCrossRef

20.

Jurisic V, Kraguljac N, Konjevic G, Spuzic I. TNF-α induced changes in cell membrane antigen expression on K-562 cells associated with increased lactate dehydrogenase (LDH) release. Neoplasma 2005;52:25–31PubMed

21.

Hofman W-K, Lubbert M, Hoelzer D, Koffler HP. Myelodysplastic syndromes. Hematol J 2004;5:1–8CrossRef

Titel: The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS
verfasst von: Gordana Bogdanović
Dimitar Jakimov
Bratislav Stojiljkovic
Vladimir Jurišić
Publikationsdatum: 01.12.2007
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 4/2007
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-007-0031-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients

A case–control study of non-alcoholic fatty liver disease in breast cancer

Two cases of sarcoidosis-lymphoma syndrome

Position-dependent expression of GADD45α in rat brain tumours

Solitary iris metastasis from breast cancer with dramatic course: case report

The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie